Highlights

The next generation sequencing market reached $231.7 million in 2012. The market is expected to reach $510.7 in 2013 and $7.6 billion in 2018 for a compound annual growth rate (CAGR) of 71.6%. The pre- and post-natal disease class as a segment was valued at $161.5 million in 2012. It is expected to reach $393.3 million in 2013 and nearly $2.1 billion in 2018, a CAGR of 39.4%. The cancer disease class as a segment was valued at $36.1 million in 2012. It is expected to reach $63.7 million in 2013 and nearly $2.5 billion in 2018, a CAGR of 108.3%.

STUDY GOALS AND OBJECTIVES

BCC Research’s goal for this study is to provide an in-depth analysis of the clinical next generation sequencing (NGS) industry, an emerging industry with enormous market potential. The approach of analyzing the industry is taken in terms of workflow (e.g., sequencers, sequence capture, informatics) and key indications where NGS diagnostics will have market share by 2018. BCC Research examines the markets for NGS diagnostics for the years 2012, 2013 and 2018. The global NGS diagnostic markets are characterized and quantified by disease indication, test complexity, test purpose and geography. Market segments that provide exciting growth opportunities include cancer, rare genetic diseases and prenatal screening. The report provides a comprehensive discussion of NGS technologies, clinical applications, industry structure, important clinical sequencing initiatives, global markets, patent status and companies. The report is designed to aid companies in their strategic planning efforts for clinical genetic testing.

REASONS FOR DOING THE STUDY

The Human Genome Project (HGP) moved DNA sequencing technology to the forefront of life science research as a genetic analysis tool. The HGP relied heavily on Sanger sequencing by capillary electrophoresis to decipher the DNA sequence of the bases in the human genome. The HGP led to significant improvements in the efficiency and costs of DNA sequencing. During this time period, the sequencing industry consolidated, resulting in one dominant company, Applied Biosystems (now Life Technologies). Beginning in 2005, the launch of next generation sequencing technologies radically changed the structure of the industry and opened up exciting new market applications. The costs of sequencing have rapidly reduced to the point where it is now feasible for complex NGS tests to be priced in the range of other multiplex genetic tests. As a result, opportunities emerged in clinical applications that are currently reaching fruition. The NGS clinical market is still relatively young and emerging, yet it holds great commercial promise. Clinical value has been shown for many applications, and several launched tests are having good commercial success. This shows that both patients and physicians are recognizing the value of NGS tests. Several molecular genetic tests that have been successful on non-NGS formats will run on NGS platforms in the future. At the same time, payors and insurance companies are beginning to provide coverage for these tests, further enhancing their commercial potential. These technical and market factors are driving this market so that in 2013, it is timely to examine the clinical segment of the sequencing industry.

CONTRIBUTION OF THE STUDY AND INTENDED AUDIENCE

This report fills a gap in the industry because its sole focus is on clinical applications run on next generation sequencing instruments. The industry is still emerging, so there is little information available regarding the applications for which NGS platforms will be used. The report provides a roadmap for understanding the ways in which next generation sequencing will be used in the diagnostic business during the next five years. It is a useful guide for strategic and business planning, as well as for learning about the impact new sequencing technologies will have in clinical diagnostics. This market report will be useful to many companies involved in the clinical, genetic testing and sequencing industries. It will be particularly valuable for companies in such industries as life science research tools, NGS instruments, molecular diagnostics, informatics clinical laboratories, pharmaceutical, biotechnology, microfluidics, lab-on-a-chip and sample preparation.

SCOPE AND FORMAT

The scope of the report includes clinical NGS technologies, applications, industries, initiatives, patents and companies. The markets for NGS-based diagnostics are given for the years 2012, 2013 and 2018. This report reviews the main sequencing technologies and explains why genetic variation is important in clinical testing. It then discusses some of the top research initiatives that are contributing to clinical NGS applications. Market driving forces are also discussed. The report examines the markets by test complexity, indication and test purpose. Test complexity refers to the multiplexing (e.g., the number of genes covered) and coverage (e.g., the extent to which the genome is covered) of the test. Examining the market by test complexity provides valuable insight into which products (e.g., sample preparation, NGS instrument, informatics) will be in demand in the future. The report provides market data and forecasts for NGS diagnostics by specific applications, including those for cancer, rare diseases, common diseases, and pre- and post-natal screening. Specific geographic markets are discussed, including North America, Europe, China, Japan and the rest of the world. Market data covers the years 2012, 2013 and 2018. Industry sectors analyzed include NGS instruments, target enrichment, informatics, clinical laboratories and the prenatal screening industry. More than 110 companies in the clinical NGS industry are profiled in this report. BCC Research provides a summary of the main industry acquisitions and strategic alliances from 2011 through 2013, including key alliance trends.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. BCC Research examined each of the key end-user market segments that will be commercially important during the next five years: cancer, rare genetic disorders, common disorders, and pre- and post-natal screening. Based on this analysis, the current and future applications of NGS technologies are evaluated in each of the major clinical market segments and sales revenues are forecast for 2013 through 2018. Based on analysis of both secondary and primary market sources, as well as the key trends in the industry, the report provides the current and projected market size for the various clinical NGS segments for the years 2012, 2013 and 2018.

Table Of Contents

CHAPTER 1 INTRODUCTION 2
STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THE STUDY 2
CONTRIBUTION OF THE STUDY AND INTENDED AUDIENCE 3
SCOPE AND FORMAT 3
METHODOLOGY 4
INFORMATION SOURCES 4
RELATED BCC REPORTS 4
ANALYST CREDENTIALS 4
BCC ONLINE SERVICES 5
DISCLAIMER 5
CHAPTER 2 EXECUTIVE SUMMARY 7
EXECUTIVE SUMMARY 7
SUMMARY TABLE CLINICAL NEXT GENERATION SEQUENCING MARKET BY DISEASE
CLASS, THROUGH 2018 ($ MILLIONS) 8
SUMMARY FIGURE CLINICAL NEXT GENERATION SEQUENCING MARKET BY DISEASE
CLASS, 2012-2018 ($ MILLIONS) 8
CHAPTER 3 OVERVIEW 11
INTRODUCTION 11
TABLE 1 REPORT SCOPE 11
CLINICAL NEXT GENERATION SEQUENCING MARKETS 12
TABLE 2 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY
DISEASE, THROUGH 2018 ($ MILLIONS) 12
CLINICAL NEXT GENERATION SEQUENCING GROWTH DRIVING FORCES 13
TECHNOLOGY DRIVERS 13
TABLE 3 KEY TECHNOLOGY DRIVERS FOR CLINICAL NEXT GENERATION
SEQUENCING 13
MARKET DRIVERS 14
TABLE 4 CLINICAL NEXT GENERATION SEQUENCING MARKET DRIVING FORCES 15
CLINICAL NEXT GENERATION SEQUENCING APPLICATIONS 15
TABLE 5 CLINICAL NEXT GENERATION SEQUENCING APPLICATION STATUS 16
CLINICAL NEXT GENERATION SEQUENCING INDUSTRY 16
TABLE 6 KEY DIAGNOSTIC NEXT GENERATION SEQUENCING INDUSTRY
PARTICIPANTS BY SECTOR 17
CHAPTER 4 TECHNOLOGIES 20
IMPORTANCE OF DNA 20
TABLE 7 DNA CHEMICAL BUILDING BLOCKS 20
TABLE 8 DNA TRANSLATION AND TRANSCRIPTION 20
TABLE 9 LONG-RANGE DNA STRUCTURE 21
GENETIC VARIATION AND ANALYSIS 22
TABLE 10 GENETIC VARIANT TYPES 22
GENETIC ANALYSIS TECHNOLOGIES 23
TABLE 11 IMPORTANT MOLECULAR DIAGNOSTIC PLATFORMS BY COMPANY 23
NEXT GENERATION SEQUENCING IN CLINICAL APPLICATIONS 24
TABLE 12 GENETIC TESTING EVOLUTION 24
TABLE 13 KEY NEAR- TO MID-TERM SEGMENTS FOR NEXT GENERATION
SEQUENCING DIAGNOSTICS 25
NEXT GENERATION SEQUENCING TECHNOLOGIES 26
HISTORY OF DNA SEQUENCING 26
TABLE 14 DNA SEQUENCING HISTORICAL TIMELINE, 1977-2013 27
TABLE 15 SEQUENCING TECHNOLOGY DEVELOPMENT, 1990-2013 32
TABLE 16 EFFECT OF NEW SEQUENCING TECHNOLOGIES ON COST AND TIME TO
SEQUENCE A SINGLE HUMAN GENOME, 2001 AND 2013 ($) 33
SANGER SEQUENCING TECHNOLOGY 33
TABLE 17 SANGER SEQUENCING SUMMARY 33
TABLE 18 SANGER SEQUENCING IMPROVEMENTS 34
NEXT GENERATION SEQUENCING PLATFORMS 34
TABLE 19 NEXT GENERATION SEQUENCING TECHNOLOGIES 35
TABLE 20 ROCHE NEXT GENERATION SEQUENCING WORKFLOW 35
TABLE 21 ILLUMINA NEXT GENERATION SEQUENCING WORKFLOW 36
TABLE 22 LIFE TECHNOLOGIES NEXT GENERATION SEQUENCING WORKFLOW 37
BENCHTOP SEQUENCERS 38
TABLE 23 BENCHTOP SEQUENCER PLATFORMS , 2010-2012 38
INFORMATICS TECHNOLOGIES 39
TABLE 24 NEXT GENERATION SEQUENCING BIOINFORMATICS WORKFLOW 39
BASE CALLING 40
MAPPING TO A REFERENCE SEQUENCE 40
TABLE 25 SEQUENCE ANNOTATION STEPS 41
VARIANT ANALYSIS 41
FUTURE TECHNOLOGY CHALLENGES 42
TABLE 26 FUTURE CHALLENGES FOR IMPLEMENTING CLINICAL NEXT GENERATION
SEQUENCING 42
TOP TEN CLINICAL NEXT GENERATION SEQUENCING INITIATIVES 43
TABLE 27 TOP 10 CLINICAL NEXT GENERATION SEQUENCING PROJECTS 43
1,000 GENOMES PROJECT 44
ARCHON X PRIZE IN GENOMICS 44
BASIC3 PROJECT 45
CANCER GENOME ATLAS 45
CANCER MOON SHOTS PROGRAM 46
CLARITY CHALLENGE 47
ENCODE PROJECT 47
GENOME IN A BOTTLE 47
MILLION VETERAN PROGRAM 48
NEUROMICS CONSORTIUM 48
CHAPTER 5 CLINICAL NEXT GENERATION SEQUENCING APPLICATIONS 50
INTRODUCTION 50
TABLE 28 CLINICAL NEXT GENERATION SEQUENCING NEAR- TO MID-TERM
APPLICATIONS 50
CANCER APPLICATIONS 51
TABLE 29 CANCER APPLICATIONS 51
MENDELIAN DISORDERS APPLICATIONS 53
TABLE 30 MENDELIAN DISORDERS APPLICATIONS 53
SCREENING APPLICATIONS 54
TABLE 31 SCREENING APPLICATIONS 54
TABLE 32 ETHICAL ISSUES ASSOCIATED WITH PRENATAL AND NEWBORN
SCREENING 57
INFECTIOUS DISEASE APPLICATIONS 57
TABLE 33 INFECTIOUS DISEASE APPLICATIONS 57
COMMON DISORDERS APPLICATIONS 59
TABLE 34 COMMON DISORDER APPLICATIONS 60
CHAPTER 6 CLINICAL NEXT GENERATION SEQUENCING INDUSTRY 63
INTRODUCTION 63
TABLE 35 KEY SEGMENTS WITHIN THE NEXT GENERATION SEQUENCING CLINICAL
INDUSTRY 63
NEXT GENERATION SEQUENCING INSTRUMENT INDUSTRY 63
TABLE 36 NEXT GENERATION SEQUENCING INSTRUMENT COMPANIES:
COMMERCIAL PHASE 64
TABLE 37 NEXT GENERATION SEQUENCING INSTRUMENT COMPETITOR MARKET
SHARE INSTALLED INSTRUMENT BASE, JUNE 2013 65
TABLE 38 NEXT GENERATION SEQUENCING HIGH-THROUGHPUT INSTRUMENT
COMPETITOR MARKET SHARE INSTALLED INSTRUMENT BASE, JUNE 2013 66
TABLE 39 NEXT GENERATION SEQUENCING BENCHTOP INSTRUMENT COMPETITOR
MARKET SHARE INSTALLED INSTRUMENT BASE, JUNE 2013 67
NEXT GENERATION SEQUENCING TARGET ENRICHMENT INDUSTRY 68
TABLE 40 NEXT GENERATION SEQUENCING-BASED TARGET ENRICHMENT
INDUSTRY 68
NEXT GENERATION SEQUENCING CLINICAL INFORMATICS INDUSTRY 69
TABLE 41 NEXT GENERATION SEQUENCING CLINICAL INFORMATICS COMPANY
POSITIONING 70
CLINICAL LABORATORY INDUSTRY 71
TABLE 42 LEADING U.S. CLINICAL LABORATORY IMPROVEMENT AMENDMENTS
LABORATORIES WITH NEXT GENERATION SEQUENCING DIAGNOSTICS 72
PRENATAL DIAGNOSTICS INDUSTRY 73
TABLE 43 NEXT GENERATION SEQUENCING-BASED PRENATAL DIAGNOSTICS
INDUSTRY 74
TABLE 44 NORTH AMERICAN TEST COSTS AND PRICES ($) 75
TABLE 45 NEXT GENERATION SEQUENCING-BASED NON-INVASIVE PRENATAL
DIAGNOSTIC MARKET SHARE BY TEST REVENUE, 2013 (%) 76
TABLE 46 NON-INVASIVE PRENATAL DIAGNOSTICS POTENTIAL FUTURE
COMPETITORS 77
CLINICAL NEXT GENERATION SEQUENCING INDUSTRY ACQUISITIONS AND
STRATEGIC ALLIANCES 78
ACQUISITIONS 78
TABLE 47 CLINICAL NEXT GENERATION SEQUENCING INDUSTRY ACQUISITIONS,
2011-2013 79
STRATEGIC ALLIANCES 81
TABLE 48 CLINICAL NEXT GENERATION SEQUENCING STRATEGIC ALLIANCES,
2011-2013 82
CHAPTER 7 NEXT GENERATION SEQUENCING DIAGNOSTICS MARKETS 92
GROWTH DRIVING FORCES 92
TABLE 49 CLINICAL NEXT GENERATION SEQUENCING KEY GROWTH DRIVING
FORCES, THROUGH 2018 92
GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET 93
TABLE 50 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY
DISEASE, THROUGH 2018 ($ MILLIONS) 93
TABLE 51 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY TEST
COMPLEXITY, THROUGH 2018 ($ MILLIONS) 95
TABLE 52 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY TEST
PURPOSE, THROUGH 2018 ($ MILLIONS) 96
NEXT GENERATION SEQUENCING CANCER DIAGNOSTIC MARKETS 97
TABLE 53 GLOBAL NEXT GENERATION SEQUENCING CANCER DIAGNOSTIC MARKET
BY MARKET SEGMENT, THROUGH 2018 ($ MILLIONS) 97
TABLE 54 GLOBAL NEXT GENERATION SEQUENCING CANCER DIAGNOSTIC MARKET
BY TEST PURPOSE, THROUGH 2018 ($ MILLIONS) 98
TABLE 55 GLOBAL CANCER NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET
BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 99
NEXT GENERATION SEQUENCING CARDIOVASCULAR DIAGNOSTIC MARKETS 100
TABLE 56 GLOBAL NEXT GENERATION SEQUENCING CARDIOVASCULAR
DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 ($ MILLIONS) 101
TABLE 57 GLOBAL NEXT GENERATION SEQUENCING CARDIOLOGY DIAGNOSTIC
MARKET BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 102
NEXT GENERATION SEQUENCING MENDELIAN DISORDERS DIAGNOSTIC
MARKETS 102
TABLE 58 GLOBAL NEXT GENERATION SEQUENCING MENDELIAN DISORDER
DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 ($ MILLIONS) 103
TABLE 59 GLOBAL NEXT GENERATION SEQUENCING MENDELIAN DISORDER
DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 104
NEXT GENERATION SEQUENCING METABOLIC AND IMMUNE DISORDER
DIAGNOSTIC MARKETS 105
TABLE 60 GLOBAL NEXT GENERATION SEQUENCING METABOLIC AND IMMUNE
DISORDER DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 ($ MILLIONS) 105
TABLE 61 GLOBAL NEXT GENERATION SEQUENCING METABOLIC AND IMMUNE
DISORDER DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 ($
MILLIONS)
106
NEXT GENERATION SEQUENCING NEUROLOGY DIAGNOSTIC MARKETS 106
TABLE 62 GLOBAL NEXT GENERATION SEQUENCING NEUROLOGY DIAGNOSTIC
MARKET FOR ALZHEIMER'S DISEASE BY TEST PURPOSE, THROUGH 2018 ($
MILLIONS)
107
TABLE 63 GLOBAL NEXT GENERATION SEQUENCING NEUROLOGY DIAGNOSTIC
MARKET BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 108
NEXT GENERATION SEQUENCING NEWBORN SCREENING DIAGNOSTIC MARKETS 108
TABLE 64 GLOBAL NEXT GENERATION SEQUENCING NEWBORN SCREENING
DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 ($ MILLIONS) 109
TABLE 65 GLOBAL NEXT GENERATION SEQUENCING NEWBORN SCREENING
DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 110
NEXT GENERATION SEQUENCING PRENATAL DIAGNOSTIC MARKETS 110
TABLE 66 GLOBAL NEXT GENERATION SEQUENCING PRENATAL DIAGNOSTIC
MARKET BY TEST PURPOSE, THROUGH 2018 ($ MILLIONS) 111
TABLE 67 GLOBAL NEXT GENERATION SEQUENCING PRENATAL DIAGNOSTIC
MARKET BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 112
NEXT GENERATION SEQUENCING FOOD-BORNE ILLNESS DIAGNOSTIC MARKETS 113
TABLE 68 GLOBAL NEXT GENERATION SEQUENCING FOOD-BORNE ILLNESS
DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 ($ MILLIONS) 113
TABLE 69 GLOBAL NEXT GENERATION SEQUENCING FOOD-BORNE ILLNESS
DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 114
NEXT GENERATION SEQUENCING HUMAN LEUKOCYTE ANTIGEN TYPING
DIAGNOSTIC MARKETS 114
TABLE 70 GLOBAL NEXT GENERATION SEQUENCING HUMAN LEUKOCYTE ANTIGEN
TYPING DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 ($ MILLIONS) 115
TABLE 71 GLOBAL NEXT GENERATION SEQUENCING HUMAN LEUKOCYTE ANTIGEN
TYPING DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 116
NEXT GENERATION SEQUENCING DIAGNOSTIC MARKETS BY GEOGRAPHY 116
TABLE 72 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY
REGION, THROUGH 2018 ($ MILLIONS) 117
NORTH AMERICA 117
TABLE 73 NORTH AMERICAN NEXT GENERATION SEQUENCING DIAGNOSTIC
MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 117
EUROPE 118
TABLE 74 EUROPEAN NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY
APPLICATION, THROUGH 2018 ($ MILLIONS) 118
CHINA 119
TABLE 75 CHINESE NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY
APPLICATION, THROUGH 2018 ($ MILLIONS) 119
JAPAN 120
TABLE 76 JAPANESE NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY
APPLICATION, THROUGH 2018 ($ MILLIONS) 120
REST OF WORLD 121
TABLE 77 REST OF WORLD NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET
BY APPLICATION, THROUGH 2018 ($ MILLIONS) 121
CHAPTER 8 PATENTS 123
CLINICAL NEXT GENERATION SEQUENCING PATENTS 123
TABLE 78 CLINICAL NEXT GENERATION SEQUENCING PATENTS, 2002-2012 123
CLINICAL NEXT GENERATION SEQUENCING PATENTS BY INDICATION 123
TABLE 79 CLINICAL NEXT GENERATION SEQUENCING PATENTS BY INDICATION,
2002-2012 123
CLINICAL NEXT GENERATION SEQUENCING PATENT ISSUES 124
POSSIBILITY OF WHOLE-GENOME SEQUENCING VIOLATING SINGLE-GENE
PATENTS 124
TABLE 80 COMPOSITION OF MATTER CLAIMS RELATING TO SINGLE-GENE PATENTS 125
STATUS OF SEQUENOM'S '054 PATENT LITIGATION 126
CHAPTER 9 COMPANY PROFILES 129
23ANDME INC. 129
TABLE 81 DATA NEEDS 129
ADAPTIVE BIOTECHNOLOGIES INC. 130
AGILENT TECHNOLOGIES INC. 131
ALMAC GROUP LTD. 132
AMBRY GENETICS 133
APPISTRY INC. 134
ARPEGGI INC. 134
ASTRID BIOSCIENCE GMBH 134
ASSURERX HEALTH 135
ASURAGEN INC. 135
BASE4INNOVATION LTD. 136
BECKMAN COULTER 136
BERRY GENOMICS CO. LTD. 137
BGI 138
BINA TECHNOLOGIES INC. 139
CARIS LIFE SCIENCES 140
CHRONIX BIOMEDICAL 140
CORIELL LIFE SCIENCES INC. 141
CORRELAGEN DIAGNOSTICS INC. 141
COUNSYL INC. 142
COURTAGEN LIFE SCIENCES INC. 142
CYPHER GENOMICS INC. 143
CYNVENIO BIOSYSTEMS INC. 143
DIOGENIX INC. 144
TABLE 82 MULTIPLE SCLEROSIS DIAGNOSTIC TECHNOLOGIES 144
DNA ELECTRONICS LTD. 145
DNA LINK 145
DNANEXUS INC. 145
ELECTRONIC BIOSCIENCES 146
EUROFINS MWG OPERON 146
EXOSOME DIAGNOSTICS INC. 147
EXPRESSION ANALYSIS INC. 148
FOUNDATION MEDICINE 149
GATC BIOTECH AG 149
GE HEALTHCARE 150
GENAPSYS 151
GENDX BV 151
GENEDX INC. 152
GENIA TECHNOLOGIES INC. 153
TABLE 83 COMMERCIAL SEQUENCER COMPETITIVE POSITIONING 153
GENOLOGICS LIFE SCIENCES SOFTWARE 154
GENOMATIX SOFTWARE GMBH 154
GENOMEQUEST INC. 155
GENOMIC HEALTH INC. 156
GIGAGEN INC. 157
GNUBIO INC. 158
GOOD START GENETICS INC. 158
ILLUMINA INC. 159
INNOVATIONS EXCHANGE PTE LTD 161
INGENUITY SYSTEMS INC. 161
INVITAE 162
IREPERTOIRE 163
KAILOS GENETICS 163
KELLBENX INC. 163
KNOME INC. 164
LABORATORY CORPORATION OF AMERICA INC. 165
LABORATORY FOR MOLECULAR MEDICINE 165
LASERGEN INC. 166
LIFE TECHNOLOGIES INC. 166
LINGVITAE HOLDING AS 168
MACROGEN INC. 169
MAVERIX BIOMICS INC. 169
MD ANDERSON CANCER CENTER 170
MEDGENOME LABS PVT. LTD. 170
MEDOMICS LLC. 170
MULTIPLICOM NV 171
MYRIAD GENETICS INC. 172
NABSYS INC. 172
NATERA INC. 173
NEWGENE LTD. 173
NOBLEGEN BIOSCIENCES 174
NOVARTIS AG 174
OMICIA INC. 175
OMIXON BIOCOMPUTING KFT 176
ONCODNA SA 176
OXFORD GENE TECHNOLOGY 177
OXFORD NANOPORE TECHNOLOGIES 177
PACIFIC BIOSCIENCES OF CALIFORNIA INC. 178
PARABASE GENOMICS 180
PATHOGENICA 180
PATHOGENETIX 181
PERKIN ELMER INC. 182
PERSONAL GENOME DIAGNOSTICS INC. 184
PERSONALIS INC. 184
PICOSEQ 185
POPULATION GENETICS TECHNOLOGIES LTD. 185
PORTABLE GENOMICS LLC 187
PREVENTIONGENETICS INC. 187
QIAGEN 188
QUANTUMDX 189
RAINDANCE TECHNOLOGIES INC. 190
REAL TIME GENOMICS INC. 191
RESPONSE GENETICS INC. 191
ROCHE HOLDING AG 191
SCIGENOM LABS 193
SENGENICS INTERNATIONAL PTE LTD. 194
SEQUENOM INC. 194
SEQUENTA INC. 195
SEQUOIA GENETICS CO. LTD. 196
SEVEN BRIDGES GENOMICS INC. 196
SIEMENS AG 197
SILICON VALLEY BIOSYSTEMS 198
SISTEMAS GENOMICOS 198
SOFTGENETICS LLC 199
STATION X INC. 199
STRAND LIFE SCIENCES 199
STRATOS GENOMICS INC. 200
SUNDANCE DIAGNOSTICS INC. 200
SYAPSE 201
THERMO FISHER SCIENTIFIC, INC. 201
TRANSGENOMIC INC. 202
TROVAGENE INC. 202
WARP DRIVE BIO LLC 203
YIKON GENOMICS CO. LTD. 203
ZS GENETICS 204

LIST OF TABLES

SUMMARY TABLE CLINICAL NEXT GENERATION SEQUENCING MARKET BY DISEASE
CLASS, THROUGH 2018 ($ MILLIONS) 8
TABLE 1 REPORT SCOPE 11
TABLE 2 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY
DISEASE, THROUGH 2018 ($ MILLIONS) 12
TABLE 3 KEY TECHNOLOGY DRIVERS FOR CLINICAL NEXT GENERATION SEQUENCING 13
TABLE 4 CLINICAL NEXT GENERATION SEQUENCING MARKET DRIVING FORCES 15
TABLE 5 CLINICAL NEXT GENERATION SEQUENCING APPLICATION STATUS 16
TABLE 6 KEY DIAGNOSTIC NEXT GENERATION SEQUENCING INDUSTRY
PARTICIPANTS BY SECTOR 17
TABLE 7 DNA CHEMICAL BUILDING BLOCKS 20
TABLE 8 DNA TRANSLATION AND TRANSCRIPTION 20
TABLE 9 LONG-RANGE DNA STRUCTURE 21
TABLE 10 GENETIC VARIANT TYPES 22
TABLE 11 IMPORTANT MOLECULAR DIAGNOSTIC PLATFORMS BY COMPANY 23
TABLE 12 GENETIC TESTING EVOLUTION 24
TABLE 13 KEY NEAR- TO MID-TERM SEGMENTS FOR NEXT GENERATION
SEQUENCING DIAGNOSTICS 25
TABLE 14 DNA SEQUENCING HISTORICAL TIMELINE, 1977-2013 27
TABLE 15 SEQUENCING TECHNOLOGY DEVELOPMENT, 1990-2013 32
TABLE 16 EFFECT OF NEW SEQUENCING TECHNOLOGIES ON COST AND TIME TO
SEQUENCE A SINGLE HUMAN GENOME, 2001 AND 2013 ($) 33
TABLE 17 SANGER SEQUENCING SUMMARY 33
TABLE 18 SANGER SEQUENCING IMPROVEMENTS 34
TABLE 19 NEXT GENERATION SEQUENCING TECHNOLOGIES 35
TABLE 20 ROCHE NEXT GENERATION SEQUENCING WORKFLOW 35
TABLE 21 ILLUMINA NEXT GENERATION SEQUENCING WORKFLOW 36
TABLE 22 LIFE TECHNOLOGIES NEXT GENERATION SEQUENCING WORKFLOW 37
TABLE 23 BENCHTOP SEQUENCER PLATFORMS , 2010-2012 38
TABLE 24 NEXT GENERATION SEQUENCING BIOINFORMATICS WORKFLOW 39
TABLE 25 SEQUENCE ANNOTATION STEPS 41
TABLE 26 FUTURE CHALLENGES FOR IMPLEMENTING CLINICAL NEXT GENERATION
SEQUENCING 42
TABLE 27 TOP 10 CLINICAL NEXT GENERATION SEQUENCING PROJECTS 43
TABLE 28 CLINICAL NEXT GENERATION SEQUENCING NEAR- TO MID-TERM
APPLICATIONS 50
TABLE 29 CANCER APPLICATIONS 51
TABLE 30 MENDELIAN DISORDERS APPLICATIONS 53
TABLE 31 SCREENING APPLICATIONS 54
TABLE 32 ETHICAL ISSUES ASSOCIATED WITH PRENATAL AND NEWBORN
SCREENING 57
TABLE 33 INFECTIOUS DISEASE APPLICATIONS 57
TABLE 34 COMMON DISORDER APPLICATIONS 60
TABLE 35 KEY SEGMENTS WITHIN THE NEXT GENERATION SEQUENCING CLINICAL
INDUSTRY 63
TABLE 36 NEXT GENERATION SEQUENCING INSTRUMENT COMPANIES: COMMERCIAL
PHASE 64
TABLE 37 NEXT GENERATION SEQUENCING INSTRUMENT COMPETITOR MARKET
SHARE INSTALLED INSTRUMENT BASE, JUNE 2013 65
TABLE 38 NEXT GENERATION SEQUENCING HIGH-THROUGHPUT INSTRUMENT
COMPETITOR MARKET SHARE INSTALLED INSTRUMENT BASE, JUNE 2013 66
TABLE 39 NEXT GENERATION SEQUENCING BENCHTOP INSTRUMENT COMPETITOR
MARKET SHARE INSTALLED INSTRUMENT BASE, JUNE 2013 67
TABLE 40 NEXT GENERATION SEQUENCING-BASED TARGET ENRICHMENT INDUSTRY 68
TABLE 41 NEXT GENERATION SEQUENCING CLINICAL INFORMATICS COMPANY
POSITIONING 70
TABLE 42 LEADING U.S. CLINICAL LABORATORY IMPROVEMENT AMENDMENTS
LABORATORIES WITH NEXT GENERATION SEQUENCING DIAGNOSTICS 72
TABLE 43 NEXT GENERATION SEQUENCING-BASED PRENATAL DIAGNOSTICS
INDUSTRY 74
TABLE 44 NORTH AMERICAN TEST COSTS AND PRICES ($) 75
TABLE 45 NEXT GENERATION SEQUENCING-BASED NON-INVASIVE PRENATAL
DIAGNOSTIC MARKET SHARE BY TEST REVENUE, 2013 (%) 76
TABLE 46 NON-INVASIVE PRENATAL DIAGNOSTICS POTENTIAL FUTURE
COMPETITORS 77
TABLE 47 CLINICAL NEXT GENERATION SEQUENCING INDUSTRY ACQUISITIONS,
2011-2013 79
TABLE 48 CLINICAL NEXT GENERATION SEQUENCING STRATEGIC ALLIANCES,
2011-2013 82
TABLE 49 CLINICAL NEXT GENERATION SEQUENCING KEY GROWTH DRIVING
FORCES, THROUGH 2018 92
TABLE 50 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY
DISEASE, THROUGH 2018 ($ MILLIONS) 93
TABLE 51 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY TEST
COMPLEXITY, THROUGH 2018 ($ MILLIONS) 95
TABLE 52 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY TEST
PURPOSE, THROUGH 2018 ($ MILLIONS) 96
TABLE 53 GLOBAL NEXT GENERATION SEQUENCING CANCER DIAGNOSTIC MARKET
BY MARKET SEGMENT, THROUGH 2018 ($ MILLIONS) 97
TABLE 54 GLOBAL NEXT GENERATION SEQUENCING CANCER DIAGNOSTIC MARKET
BY TEST PURPOSE, THROUGH 2018 ($ MILLIONS) 98
TABLE 55 GLOBAL CANCER NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET
BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 99
TABLE 56 GLOBAL NEXT GENERATION SEQUENCING CARDIOVASCULAR DIAGNOSTIC
MARKET BY TEST PURPOSE, THROUGH 2018 ($ MILLIONS) 101
TABLE 57 GLOBAL NEXT GENERATION SEQUENCING CARDIOLOGY DIAGNOSTIC
MARKET BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 102
TABLE 58 GLOBAL NEXT GENERATION SEQUENCING MENDELIAN DISORDER
DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 ($ MILLIONS) 103
TABLE 59 GLOBAL NEXT GENERATION SEQUENCING MENDELIAN DISORDER
DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 104
TABLE 60 GLOBAL NEXT GENERATION SEQUENCING METABOLIC AND IMMUNE
DISORDER DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 ($ MILLIONS) 105
TABLE 61 GLOBAL NEXT GENERATION SEQUENCING METABOLIC AND IMMUNE
DISORDER DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 106
TABLE 62 GLOBAL NEXT GENERATION SEQUENCING NEUROLOGY DIAGNOSTIC
MARKET FOR ALZHEIMER'S DISEASE BY TEST PURPOSE, THROUGH 2018 ($
MILLIONS)
107
TABLE 63 GLOBAL NEXT GENERATION SEQUENCING NEUROLOGY DIAGNOSTIC
MARKET BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 108
TABLE 64 GLOBAL NEXT GENERATION SEQUENCING NEWBORN SCREENING
DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 ($ MILLIONS) 109
TABLE 65 GLOBAL NEXT GENERATION SEQUENCING NEWBORN SCREENING
DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 110
TABLE 66 GLOBAL NEXT GENERATION SEQUENCING PRENATAL DIAGNOSTIC
MARKET BY TEST PURPOSE, THROUGH 2018 ($ MILLIONS) 111
TABLE 67 GLOBAL NEXT GENERATION SEQUENCING PRENATAL DIAGNOSTIC
MARKET BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 112
TABLE 68 GLOBAL NEXT GENERATION SEQUENCING FOOD-BORNE ILLNESS
DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 ($ MILLIONS) 113
TABLE 69 GLOBAL NEXT GENERATION SEQUENCING FOOD-BORNE ILLNESS
DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 114
TABLE 70 GLOBAL NEXT GENERATION SEQUENCING HUMAN LEUKOCYTE ANTIGEN
TYPING DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 ($ MILLIONS) 115
TABLE 71 GLOBAL NEXT GENERATION SEQUENCING HUMAN LEUKOCYTE ANTIGEN
TYPING DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 116
TABLE 72 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY
REGION, THROUGH 2018 ($ MILLIONS) 117
TABLE 73 NORTH AMERICAN NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET
BY APPLICATION, THROUGH 2018 ($ MILLIONS) 117
TABLE 74 EUROPEAN NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY
APPLICATION, THROUGH 2018 ($ MILLIONS) 118
TABLE 75 CHINESE NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY
APPLICATION, THROUGH 2018 ($ MILLIONS) 119
TABLE 76 JAPANESE NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY
APPLICATION, THROUGH 2018 ($ MILLIONS) 120
TABLE 77 REST OF WORLD NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET
BY APPLICATION, THROUGH 2018 ($ MILLIONS) 121
TABLE 78 CLINICAL NEXT GENERATION SEQUENCING PATENTS, 2002-2012 123
TABLE 79 CLINICAL NEXT GENERATION SEQUENCING PATENTS BY INDICATION,
2002-2012 123
TABLE 80 COMPOSITION OF MATTER CLAIMS RELATING TO SINGLE-GENE PATENTS 125
TABLE 81 DATA NEEDS 129
TABLE 82 MULTIPLE SCLEROSIS DIAGNOSTIC TECHNOLOGIES 144
TABLE 83 COMMERCIAL SEQUENCER COMPETITIVE POSITIONING 153
BIO126A - Next Generation Sequencing: Emerging Clinical Applications and Global Markets
SUMMARY FIGURE CLINICAL NEXT GENERATION SEQUENCING MARKET BY DISEASE
CLASS, 2012-2018 ($ MILLIONS)

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Global Next-generation Sequencing Trends

Global Next-generation Sequencing Trends

  • $ 12 500
  • Industry report
  • September 2014
  • by Frost & Sullivan

An End-user Perspective The overall research objective was to capture and analyze global next-generation (NGS) sequencing trends and use. Most researchers outsource NGS technologies; however, in-house ...

Single Nucleotide Polymorphism (SNP) Genotyping: Technologies and Global Markets

Single Nucleotide Polymorphism (SNP) Genotyping: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • September 2014
  • by BCC Research

This BCC Research report discusses market growth, size and opportunities with respect to applications, geographic region and technologies. Forecast trends and revenue are given through 2019. Major players, ...

MicroRNA Research Tools, Diagnostics and Therapeutics: Global Markets

MicroRNA Research Tools, Diagnostics and Therapeutics: Global Markets

  • $ 6 650
  • Industry report
  • September 2014
  • by BCC Research

This BCC Research report provides an overview of the current state of the microRNA (miRNA) market, focusing mainly on continuing research endeavors, newly emerging sophisticated tools, reagents, techniques, ...

Global Bioinformatics Industry

July 2014 $ 4 950

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.